Tenvie Therapeutics initiated Phase 1 first-in-human trials for TNV313, a small molecule NLRP3 inhibitor designed to cross the blood-brain barrier. The company plans to publish preliminary safety and pharmacokinetic data in the first half of 2027.
Tenvie Therapeutics initiated Phase 1 first-in-human trials for TNV313, a small molecule NLRP3 inhibitor designed to cross the blood-brain barrier. The company plans to publish preliminary safety and pharmacokinetic data in the first half of 2027.